GlassScriptPhysician profile
Robert J Bacon
NPI 1700951704
$7,024.92
in general payments reported to CMS, 2019-2025
27 companies · $2,112 in 2025
The $2,112 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $535 · 2021: $728 · 2022: $967 · 2023: $911 · 2024: $1,387 · 2025: $2,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,409.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,244.49 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,048.12 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $741.23 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $590.78 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $485.28 | 2022-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $470.87 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $340.23 | 2019-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $329.07 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $309.79 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $300.31 | 2019-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Allergan, INC. | $191.24 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $184.43 | 2024-2025 | Cobenfy |
| Eisai INC. | $130.31 | 2020-2022 | |
| Noven Therapeutics, LLC | $126.03 | 2022-2025 | Xelstrym, Secuado |
| Bausch Health US, LLC | $87.64 | 2024-2025 | Aplenzin |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $78.11 | 2019-2024 | Perseris |
| Idorsia Pharmaceuticals US INC | $76.21 | 2022-2025 | Quviviq, Quviviq |
| Corium, LLC | $55.24 | 2022-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $53.80 | 2022-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $44.50 | 2022-2025 | Abilify Asimtufii |
| Neuronetics, INC. | $23.38 | 2020 | |
| Shire North American Group INC | $20.81 | 2019 | |
| Almatica Pharma LLC | $20.55 | 2024 | Loreev Xr |
| Currax Pharmaceuticals LLC | $19.58 | 2019 | |
| Si-Bone, INC. | $18.61 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.42 | 2019 | |
| Merck Sharp & Dohme LLC | $16.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bacon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.